Molecular Cancer

CORRECTION

Open Access

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Yann Cheli[1*], Meri K. Tulic[2], Najla El Hachem[3], Nicolas Nottet[1], Arnaud Jacquel[4], Maeva Gesson[5], Thomas Strub[1], Karine Bille[1], Alexandra Picard-Gauci[6], Henri Montaudié[6], Guillaume E. Beranger[1,2], Thierry Passeron[2,6], Pierre Close[3], Corine Bertolotto[1†] and Robert Ballotti[1†]

Correction to: Mol Cancer (2021) 20:12
https://doi.org/10.1186/s12943-020-01306-2

Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12943-021-01319-5.

> **Additional file 1.**

Author details
The online version contains supplementary material available at https://doi.org/10.1186/s12943-021-01319-5.
[1]Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000 Nice, France. [2]Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000 Nice, France. [3]Laboratory of Cancer Signaling, University of Liège, Liège, Belgium. [4]Université Nice Côte d'Azur, INSERM, U1065, Team2 Cell death, differentiation and cancer, 06000 Nice, France. [5]Université Nice Côte d'Azur, INSERM, U1065, Imaging platform, 06000 Nice, France. [6]CHU NICE, Département de Dermatologie, 06000 Nice, France.

The original article can be found online at https://doi.org/10.1186/s12943-020-01306-2.

* Correspondence: Yann.Cheli@univ-cotedazur.fr
†Corine Bertolotto and Robert Ballotti contributed equally to this work.
[1]Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000 Nice, France
Full list of author information is available at the end of the article

Published online: 27 January 2021

Reference
1. Cheli Y, Tulic MK, El Hachem N, et al. ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer. 2021;20:12. https://doi.org/10.1186/s12943-020-01306-2.

BMC